There are two major groups of intended users for our device.

Firstly, doctors. The software we intend to develop can be designed for clinical use, as a tool to support professionals in diagnosis. It will aid doctors in melanoma detection, improving diagnosis. This could prevent the development of complicated cases, where a false negative can allow the cancer to progress into a more advanced stage.

Secondly, patients. The software can be designed as an app, for universal use. The aim is self diagnosis, reducing the workload of doctors, especially dermatologists. This will save time, and can be very beneficial for users, especially those more prone to develop melanoma. However, a false negative can be very dangerous, therefore, the app will not be able to replace medical diagnosis.